Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2012

Open Access 01-08-2012 | Preclinical Study

Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer

Authors: Neng Wang, Zhi-Yu Wang, Sui-Lin Mo, Tjing Yung Loo, Dong-Mei Wang, Hai-Bin Luo, De-Po Yang, Yu-Ling Chen, Jian-Gang Shen, Jian-Ping Chen

Published in: Breast Cancer Research and Treatment | Issue 3/2012

Login to get access

Abstract

Anti-angiogenesis targeting VEGFR-2 has been considered as an important strategy for cancer therapy. Ellagic acid is a naturally existing polyphenol widely found in fruits and vegetables. It was reported that ellagic acid interfered with some angiogenesis-dependent pathologies. Yet the mechanisms involved were not fully understood. Thus, we analyzed its anti-angiogenesis effects and mechanisms on human breast cancer utilizing in-vitro and in-vivo methodologies. The in-silico analysis was also carried out to further analyze the structure-based interaction between ellagic acid and VEGFR-2. We found that ellagic acid significantly inhibited a series of VEGF-induced angiogenesis processes including proliferation, migration, and tube formation of endothelial cells. Besides, it directly inhibited VEGFR-2 tyrosine kinase activity and its downstream signaling pathways including MAPK and PI3K/Akt in endothelial cells. Ellagic acid also obviously inhibited neo-vessel formation in chick chorioallantoic membrane and sprouts formation of chicken aorta. Breast cancer xenografts study also revealed that ellagic acid significantly inhibited MDA-MB-231 cancer growth and P-VEGFR2 expression. Molecular docking simulation indicated that ellagic acid could form hydrogen bonds and aromatic interactions within the ATP-binding region of the VEGFR-2 kinase unit. Taken together, ellagic acid could exert anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.
Literature
1.
Coughlin SS, Ekwueme DU (2009) Breast cancer as a global health concern. Cancer Epidemiol 33:315–318PubMedCrossRef
2.
Miller KD (2004) Recent translational research: antiangiogenic therapy for breast cancer—where do we stand? Breast Cancer Res 6:128–132PubMedCrossRef
3.
4.
Khosravi Shahi P, Soria Lovelle A, Pérez Manga G (2009) Tumoral angiogenesis and breast cancer. Clin Transl Oncol 11:138–142PubMedCrossRef
5.
Senger DR, Van de Water L, Brown LF et al (1993) Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12:303–324PubMedCrossRef
6.
Kurebayashi J, Otsuki T, Kunisue H et al (1999) Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 90:977–981PubMedCrossRef
7.
Tortora G, Melisi D, Ciardiello F (2004) Angiogenesis: a target for cancer therapy. Curr Pharm Des 10:11–26PubMedCrossRef
8.
Hoeben A, Landuyt B, Highley MS et al (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549–580PubMedCrossRef
9.
10.
Guo S, Colbert LS, Fuller M et al (2010) Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta 1806:108–121PubMed
11.
Sebolt-Leopold JS, English JM (2006) Mechanisms of drug inhibition of signaling molecules. Nature 441:457–462PubMedCrossRef
12.
McTigue MA, Wickersham JA, Pinko C et al (1999) Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 7:319–330PubMedCrossRef
13.
Noble ME, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303:1800–1805PubMedCrossRef
14.
Lu J, Zhang K, Nam S, Anderson RA et al (2010) Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR-2 kinase and downstream signaling. Carcinogenesis 31:481–488PubMedCrossRef
15.
Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788–1795PubMedCrossRef
16.
Wahle KW, Brown I, Rotondo D et al (2011) Plant phenolics in the prevention and treatment of cancer. Adv Exp Med Biol 698:36–51CrossRef
17.
Athar M, Back JH, Kopelovich L et al (2009) Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 486:95–102PubMedCrossRef
18.
Gacche RN, Shegokar HD, Gond DS et al (2011) Evaluation of selected flavonoids as antiangiogenic, anticancer, and radical scavenging agents: an experimental and in silico analysis. Cell Biochem Biophys. doi:10.​1007/​s12013-011-9251-z PubMed
19.
Han DH, Lee MJ, Kim JH (2006) Antioxidant and apoptosis-inducing activities of ellagic acid. Anticancer Res 26:3601–3606PubMed
20.
Priyadarsini KI, Khopde SM, Kumar SS, Mohan H (2002) Free radical studies of ellagic acid, a natural phenolic antioxidant. J Agric Food Chem 50:2200–2206PubMedCrossRef
21.
Labrecque L, Lamy S, Chapus A et al (2005) Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis 26:821–826PubMedCrossRef
22.
Lee KH, Choi HR, Kim CH (2005) Anti-angiogenic effect of the seed extract of Benincasa hispida Cogniaux. J Ethnopharmacol 97:509–513PubMedCrossRef
23.
Losso JN, Bansode RR, Trappey A 2nd et al (2004) In vitro anti-proliferative activities of ellagic acid. J Nutr Biochem 15:672–678PubMedCrossRef
24.
Shyu KG, Tsai SC, Wang BW et al (2004) Saikosaponin C induces endothelial cells growth, migration and capillary tube formation. Life Sci 76:813–826PubMedCrossRef
25.
Auerbach R, Lewis R, Shinners B et al (2003) Angiogenesis assays: a critical overview. Clin Chem 49:32–40PubMedCrossRef
26.
Wen W, Lu J, Zhang K et al (2008) Grape seed extract inhibits angiogenesis via suppression of the vascular endothelial growth factor receptor signaling pathway. Cancer Prev Res (Phila) 1:554–561CrossRef
27.
Zhang S, Cao Z, Tian H et al (2011) SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res 17:4439–4450PubMedCrossRef
28.
Colavitti R, Pani G, Bedogni B et al (2002) Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 277:3101–3108PubMedCrossRef
29.
Price JE, Polyzos A, Zhang RD et al (1990) Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50:717–721PubMed
30.
Wang D, Stockard CR, Harkins L et al (2008) Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem 83:179–189PubMedCrossRef
31.
Harris PA, Cheung M, Hunter RN 3rd et al (2005) Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR-2 kinase inhibitors. J Med Chem 48:1610–1619PubMedCrossRef
32.
Sekiguchi Y, Nakaniwa T, Kinoshita T et al (2009) Structural insight into human CK2α in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett 19:2920–2923PubMedCrossRef
33.
34.
Paz K, Zhu Z (2005) Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Front Biosci 10:1415–1439PubMedCrossRef
35.
Gingras D, Lamy S, Béliveau R (2000) Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins. Biochem J 348:273–280PubMedCrossRef
36.
Jung MH, Lee SH, Ahn EM et al (2009) Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 30:655–661PubMedCrossRef
37.
Chung BH, Lee JJ, Kim JD et al (2010) Angiogenic activity of sesamin through the activation of multiple signal pathways. Biochem Biophys Res Commun 391:254–260PubMedCrossRef
38.
Gabriele B, Rolf B, Gerald M et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744CrossRef
39.
Shinkaruk S, Bayle M, Laïn G et al (2003) Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 3:95–117PubMedCrossRef
Metadata
Title
Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer
Authors
Neng Wang
Zhi-Yu Wang
Sui-Lin Mo
Tjing Yung Loo
Dong-Mei Wang
Hai-Bin Luo
De-Po Yang
Yu-Ling Chen
Jian-Gang Shen
Jian-Ping Chen
Publication date
01-08-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-1977-9

Other articles of this Issue 3/2012

Breast Cancer Research and Treatment 3/2012 Go to the issue

Preclinical Study

Strigolactones: a novel class of phytohormones that inhibit the growth and survival of breast cancer cells and breast cancer stem-like enriched mammosphere cells

Epidemiology

Disparities in breast cancer mortality trends in a middle income country

Epidemiology

Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990–2008

Review

Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials

Preclinical study

Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours

Epidemiology

Tumour characteristics among women with very low-risk breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits